Viamet Pharmaceuticals

About:

Viamet discovers and develops small molecule inhibitors via an enzyme binding approach for the treatment of various diseases.

Website: http://www.viamet.com

Top Investors: U.S. Department of Defense, Hatteras Venture Partners, Novartis Venture Fund, Astellas Venture Management, Intersouth Partners

Description:

Viamet Pharmaceuticals discovers and develops "best-in-class" inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, their Metallophileâ„¢ Technology. Viamet's disruptive Metallophileâ„¢ technology is based on their world-class expertise in bioinorganic chemistry and metalloenzymes and allows them to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet's best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors.